NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Fabhalta Capsules Specified Drug-use Survey

Active Not RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: C3 Glomerulopathy

Countries: Japan

The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.

Eligibility overview

Sex: ALL

Age: 0 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant).

Exclusion Criteria:

* Use of iptacopan for an indication not yet approved under the Clinical Trials Act or GCP (e.g., patient-requested medical treatment, investigator-initiated clinical trial)

Locations (29)

Nagoya, Aichi-ken, Japan
Toyoake, Aichi-ken, Japan
Hirosaki, Aomori, Japan
Chiba, Chiba, Japan
Fukuoka, Fukuoka, Japan
Kitakyushu, Fukuoka, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Tsukuba, Ibaraki, Japan
Komatsu, Ishikawa-ken, Japan
Yokohama, Kanagawa, Japan
Tosa-gun, Kyoto, Japan
Tsu, Mie-ken, Japan
Nagasaki, Nagasaki, Japan
Suita, Osaka, Japan
Takatsuki, Osaka, Japan
Kusatsu, Shiga, Japan
Ohtsu, Shiga, Japan
Shizuoka, Shizuoka, Japan
Shimotsuga Gun, Tochigi, Japan
Tokushima, Tokushima, Japan
Bunkyo-ku, Tokyo, Japan
Fuchū, Tokyo, Japan
Nakano City, Tokyo, Japan
Shinjuku Ku, Tokyo, Japan
Hiroshima, Japan
Ishikawa, Japan
Nara, Japan
Wakayama, Japan